Finance

Lists
524715:BOM
Sun Pharmaceutical Industries Ltd
₹1 760,60
+0,67%
(+11,70) 1D
15 Okt., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524715...
Open
₹1 730,00
High
₹1 777,40
Low
₹1 730,00
Mkt. cap
4,23 bn
Avg. vol.
103,70 k
Volume
77,49 k
Dividend
0,91%
Quarterly dividend
₹4,00
Ex-dividend date
07 Jul. 2026
P/E ratio
34,90
52-wk high
₹2 047,55
52-wk low
₹1 583,60
EPS
₹50,44
Shares outstanding
0,00
No. of employees
47 k
Open
₹1 730,00
High
₹1 777,40
Low
₹1 730,00
Mkt. cap
4,23 bn
Avg. vol.
103,70 k
Volume
77,49 k
Dividend
0,91%
Quarterly dividend
₹4,00
Ex-dividend date
07 Jul. 2026
P/E ratio
34,90
52-wk high
₹2 047,55
52-wk low
₹1 583,60
EPS
₹50,44
Shares outstanding
0,00
No. of employees
47 k
News stories
From web sources and news partners
Profile
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
About Sun Pharmaceutical Industries Ltd
CEO-
Employees47 k
Founded1983
HeadquartersGoregaon East, Mumbai, Indië
SectorPharmaceutical industry
Websitesunpharma.com
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
144,78 mjd
155,21 mjd
146,12 mjd
153,00 mjd
Cost of goods sold
29,83 mjd
29,45 mjd
37,36 mjd
29,63 mjd
Cost of revenue
29,83 mjd
29,45 mjd
37,36 mjd
29,63 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,65 mjd
28,92 mjd
30,60 mjd
32,27 mjd
Operating expense
81,28 mjd
85,13 mjd
80,66 mjd
87,80 mjd
Total operating expenses
111,11 mjd
114,58 mjd
118,02 mjd
117,43 mjd
Operating income
33,67 mjd
40,62 mjd
28,10 mjd
35,57 mjd
Other non operating income
4,70 mjd
5,79 mjd
-14,29 mjd
7,24 mjd
EBT including unusual items
41,55 mjd
42,07 mjd
35,37 mjd
40,89 mjd
EBT excluding unusual items
41,55 mjd
46,97 mjd
26,83 mjd
42,93 mjd
Income tax expense
10,31 mjd
8,26 mjd
8,28 mjd
11,88 mjd
Effective tax rate
24,80%
19,63%
23,40%
29,05%
Other operating expenses
46,34 mjd
48,89 mjd
42,30 mjd
48,14 mjd
Net income
31,18 mjd
33,69 mjd
27,14 mjd
28,95 mjd
Net profit margin
21,54%
21,71%
18,57%
18,92%
Earnings per share
13,00
15,48
11,30
12,71
Interest and investment income
-
-
9,74 mjd
-
Interest expense
-998,60 m
-783,60 m
-858,90 m
-996,70 m
Net interest expenses
-998,60 m
-783,60 m
8,89 mjd
-996,70 m
Depreciation and amortization charges
7,30 mjd
7,32 mjd
7,75 mjd
7,39 mjd
EBITDA
40,82 mjd
46,53 mjd
34,86 mjd
42,32 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme